Literature DB >> 12834268

Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives.

Joseph Knoll1.   

Abstract

This review is to summarize experimental evidence and theoretical consideration in support of the concept that a mesencephalic enhancer regulation is the basis of the limited number of innate drives indispensable for the survival of the individual and the species, while a specifically organized telencephalic enhancer regulation is the basis of the acquired drives to reach an unlimited number of dispensable goals. The study is also an overview of the experimental and clinical data supporting the proposal that, due to the progressive decay of the mesencephalic enhancer regulation with the passing of time, the prophylactic administration of a synthetic enhancer substance [(-)-deprenyl, (-)-BPAP] during postdevelopmental life could significantly slow the age-related decay of behavioral performances, prolong life, and prevent the precipitation or delay the onset of Parkinson's disease and Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12834268     DOI: 10.1023/a:1024224311289

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  38 in total

1.  Experimental studies on the higher nervous activity of animals. V. The functional mechanism of the active conditioned reflex.

Authors:  J KNOLL
Journal:  Acta Physiol Acad Sci Hung       Date:  1956

2.  (-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors.

Authors:  W Hamabe; R Fujita; T Yasusa; F Yoneda; A Yoshida; H Ueda
Journal:  Cell Mol Neurobiol       Date:  2000-12       Impact factor: 5.046

3.  (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

Authors:  J Knoll; F Yoneda; B Knoll; H Ohde; I Miklya
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 4.  (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.

Authors:  J Knoll
Journal:  Pharmacol Toxicol       Date:  1998-02

5.  (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release.

Authors:  S Shimazu; K Takahata; H Katsuki; H Tsunekawa; A Tanigawa; F Yoneda; J Knoll; A Akaike
Journal:  Eur J Pharmacol       Date:  2001-06-15       Impact factor: 4.432

6.  Sexual hormones terminate in the rat: the significantly enhanced catecholaminergic/serotoninergic tone in the brain characteristic to the post-weaning period.

Authors:  J Knoll; I Miklya; B Knoll; J Dalló
Journal:  Life Sci       Date:  2000-07-07       Impact factor: 5.037

7.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

8.  Effect of selegiline on dopamine concentration in the striatum of a primate.

Authors:  S Kaseda; M Nomoto; S Iwata
Journal:  Brain Res       Date:  1999-01-02       Impact factor: 3.252

9.  Multiple sigma binding sites in guinea-pig and rat brain membranes: G-protein interactions.

Authors:  J H Connick; G Hanlon; J Roberts; L France; P K Fox; C D Nicholson
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

10.  Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication.

Authors:  J Knoll; I Miklya
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

View more
  2 in total

Review 1.  The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).

Authors:  I Miklya
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

2.  The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.

Authors:  Haris Carageorgiou; Antonios C Sideris; Ioanna Messari; Chrissoula I Liakou; Stylianos Tsakiris
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.